Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147888 | 0.82 | SLC6A4 (0.54) | SLC6A4HTR6HTR2CHTR2BSLC6A2 | |
| SCHEMBL17433283 | 0.81 | HRH3 (0.50) | HTR2CHTR2B | |
| SCHEMBL19075550 | 0.79 | CHRM3 (0.44) | SLC6A4POLBSLC6A2SLC6A3CHRM3 | |
| SCHEMBL23213582 | 0.78 | HTR2C (0.47) | SLC6A4HTR6POLBHTR2CHTR2B | |
| SCHEMBL29739721 | 0.78 | HTR2C (0.47) | SLC6A4HTR6POLBHTR2CHTR2B | |
| SCHEMBL27290158 | 0.78 | HTR2C (0.53) | SLC6A4HTR6POLBHTR2CHTR2B | |
| SCHEMBL20176333 | 0.76 | SLC6A4 (0.38) | SLC6A4HTR2CHTR2BSLC6A2SLC6A3 | |
| SCHEMBL13700880 | 0.76 | SLC6A2 (0.59) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL26068819 | 0.72 | ALDH1A1 (0.43) | SLC6A4HTR6HTR2CHTR2BSLC6A2 | |
| SCHEMBL20205884 | 0.72 | GRIN1 (0.43) | SLC6A4HTR2CHTR2BSLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SLC6A4 1914/4885HTR6 1882/4885POLB 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.